News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
340
Sources here
9
Companies here
29
Search results Stored financial headlines

Active search

340 matching headlines

Ticker or company: SANAMain company stories
Clear
Latest

MarketBeat Earnings

Walleye Capital LLC Makes New $719,000 Investment in Sanara MedTech Inc. $SMTI

Walleye Capital LLC has made a new investment of $719,000 in Sanara MedTech Inc. (NASDAQ:SMTI), acquiring 30,465 shares, which represents about 0.33% of the company. Despite institutional investors collectively owning 8.10% of SMTI, analyst sentiment has weakened with several downgrades to "Hold" or "Neutral," and the company recently missed quarterly earnings and revenue estimates. Sanara MedTech specializes in …

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing

ARCH venture funds and related entities, along with several individual managers, have reported an updated collective beneficial ownership of 15.3% in Sana Biotechnology (SANA) common stock as of June 30, 2026. This amounts to 45,860,681 shares based on 299,360,637 shares outstanding. Robert Nelsen, a …

SANA main company
Sharemaestro market context Price above Trend Line 52 weeks -0.8% SANA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sana Biotechnology | SCHEDULE 13G/A: Others

This article is a Schedule 13G/A filing for Sana Biotechnology. It indicates an amendment to a previous filing, typically related to significant ownership of the company's stock by an institutional investor or beneficial owner. This is a standard regulatory disclosure.

SANA main company
Sharemaestro market context Price above Trend Line 52 weeks -0.8% SANA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3% - Should You Sell?

Sana Biotechnology (NASDAQ:SANA) shares dropped 5.3% to $3.4750 on Friday, with trading volume significantly below average. Despite the dip, analyst sentiment is mixed but leans positive, with an average target price of $9.50, although one analyst recently downgraded the stock to "Sell." The company …

SANA main company
Sharemaestro market context Price above Trend Line 52 weeks -0.8% SANA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside

Sana Biotechnology, Inc.'s average 12-month price target has been reduced slightly from $9.5 to $9.38 by 8 analysts, with individual forecasts ranging from $6 to $16 per share. Despite the cut, the new target still suggests a significant 155% potential upside based on the …

SANA main company
Sharemaestro market context Price above Trend Line 52 weeks -0.8% SANA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7

BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks …

SANA main company
Sharemaestro market context Price above Trend Line 52 weeks -0.8% SANA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context